SEC Form 4	
------------	--

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Wahl Bryan			2. Issuer Name and Ticker or Trading Symbol <u>Tarsus Pharmaceuticals, Inc.</u> [TARS]		tionship of Reporting Pe all applicable) Director	10% Owner			
(Last) C/O TARSU	st) (First) (Middle) D TARSUS PHARMACEUTICALS, INC.		3. Date of Earliest Transaction (Month/Day/Year) 03/17/2023	X	Officer (give title below) General Cou	Other (specify below) unsel			
15440 LAGUNA CANYON ROAD, SUITE 160 (Street)		ROAD, SUITE 160	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	ividual or Joint/Group Filing (Check Applicabl Form filed by One Reporting Person				
IRVINE	CA	92618			Form filed by More that Person	an One Reporting			
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication	10b5-1(c) Transaction Indication					
			Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

· · · · ·											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)						Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11150. 4)	
Common Stock	03/17/2023		S ⁽¹⁾		339	D	\$13.28	17,837	D		
Common Stock	03/20/2023		S ⁽¹⁾		357	D	\$12.61	17,480	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispe of (D	bosed D) tr. 3, 4		Expiration Date Amount of Month/Day/Year) Securities			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D)	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Remarks:

/s/ Leonard M. Greenstein,

Attorney-in-Fact

03/21/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.